ArticleMolecular cancer2005
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients.
Article in Molecular cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Phylostratigraphic analysis of gene co-expression network reveals the evolution of functional modules for ovarian cancer.Scientific reports · 2019Article
- Article
- Unbiased functional clustering of gene variants with a phenotypic-linkage network.PLoS computational biology · 2014Article
- Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo.Amino acids · 2012Article
- Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines.Journal of oncology · 2012Article
- Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.Journal of cellular and molecular medicine · 2011Article
- Article
- The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.International journal of cancer · 2010Article
- Brain neurons express ornithine decarboxylase-activating antizyme inhibitor 2 with accumulation in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2010Article
- Antizyme and antizyme inhibitor, a regulatory tango.Cellular and molecular life sciences : CMLS · 2009Review
- Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells.BMC cell biology · 2009Article
- Antizyme inhibitor 2 (AZIN2/ODCp) stimulates polyamine uptake in mammalian cells.The Journal of biological chemistry · 2008Article
- Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions.Oncogene · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundWhile numerous studies have characterized primary ovarian tumors, little information is available regarding expression patterns of metastatic sites of this cancer. To define sets of genes that distinguish primary and metastatic ovarian tumors, we used cDNA microarrays to characterize global gene expression patterns in 38 effusions (28 peritoneal, 10 pleural) and 8 corresponding primary ovarian tumors, and searched for associations between expression patterns and clinical parameters.
resultsWe observed multidimensional variation in expression patterns among the cancers. Coordinate variation in expression of genes from two chromosomal regions, 8q and 19q, was seen in subsets of the cancers indicating possible amplifications in these regions. A set of 112 unique genes of known function was differentially expressed between primary tumors and effusions using supervised analysis. Relatively few differences were seen between effusions isolated from the pleural and peritoneal cavities or between effusions from patients diagnosed with stage III and stage IV cancers. A set of 84 unique genes was identified that distinguished high from lower grade ovarian cancers. The results were corroborated using immunocytochemistry, mRNA in situ hybridization, and immunoblotting.
conclusionThe extensive variation in expression patterns observed underscores the molecular heterogeneity of ovarian cancer, but suggests a similar molecular profile for ovarian carcinoma cells in serosal cavities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.